Healthy volunteers inhale RSV virus to help fight future outbreaks
NCT ID NCT02484417
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study gave healthy adults a mild dose of respiratory syncytial virus (RSV) in a controlled hospital setting to learn how the body fights the infection. Thirty-two volunteers aged 18 to 50 stayed in isolation for about 10 days while researchers monitored symptoms, viral shedding, and immune responses. The goal is to use this knowledge to develop better vaccines and treatments for RSV, which can be severe in young children and older adults.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
RSV A2 virus (intranasal inoculation)
What this could lead to
If successful, this study could help researchers develop better treatments and vaccines for RSV, which can be dangerous for children and older adults.
What could go wrong
This is an early-phase study with only 32 participants, so results may not apply broadly. The virus is expected to cause only mild cold symptoms, but unexpected reactions are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for UPPER RESPIRATORY TRACT INFECTION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States